Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference

Rhea-AI Summary

Passage Bio (NASDAQ: PASG) announced that Will Chou, M.D., president and chief executive officer, will participate in a panel at the Chardan 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 3:30 p.m. ET in New York City.

A live webcast will be available on the company’s Investors & News webpage at investors.passagebio.com, and a replay will be accessible for 90 days following the event.

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a panel discussion during the Chardan 9^th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 3:30 p.m. ET in New York City.

A live webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. A replay of the event will be available for 90 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. 

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

FAQ

When will Passage Bio (NASDAQ: PASG) present at the Chardan 9th Annual Genetic Medicines Conference?

Passage Bio's CEO will participate on October 21, 2025 at 3:30 p.m. ET.

How can investors watch Passage Bio's (PASG) panel at the Chardan Genetic Medicines Conference?

A live webcast will be available on Passage Bio's Investors & News webpage at investors.passagebio.com.

Will there be a replay of Passage Bio's (PASG) Chardan conference presentation and for how long?

Yes. A replay will be available for 90 days after the event on the company's investor site.

Who will represent Passage Bio (PASG) at the Chardan 9th Annual Genetic Medicines Conference?

Will Chou, M.D., president and chief executive officer, will participate in a panel discussion.

Where is the Chardan 9th Annual Genetic Medicines Conference taking place for Passage Bio's (PASG) presentation?

The panel takes place in New York City on October 21, 2025.